In DESTINY-Breast 01, T-DXd demonstrated a confirmed response of 60.9% in patients with metastatic HER2+ breast cancer previously treated with T-DM1, with a median progression-free survival of 16.4 months [20]. Here, ERBB2 is linked to breast carcinoma.